Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fluorouracil 38Capecitabine 31Oxaliplatin 30Leucovorin 30Radiotherapy 21Irinotecan 20Bevacizumab 15Radiation 12Cetuximab 12pembrolizumab 9Gemcitabine 7trifluridine tipiracil drug combination 5dehydroftorafur 5cediranib 5Radiotherapy, Intensity-Modulated 5Folfox protocol 5Erlotinib Hydrochloride 5Cisplatin 5Carboplatin 5trametinib 4Surgical Procedures, Operative 4Paclitaxel 4Neoadjuvant Therapy 4Gene Expression Profiling 4Cyclophosphamide 4sargramostim 3binimetinib 3Trifluridine 3Sorafenib 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rectal Neoplasms × HMPL-013 × Clear all
NCT03251378 2024-09-25

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Hutchmed

Phase 1 Completed
129 enrolled 32 charts
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡